99 related articles for article (PubMed ID: 28436708)
21. A versatile in vitro ELISA test for quantification and quality testing of infectious, inactivated and formulated rabies virus used in veterinary monovalent or combination vaccine.
Sigoillot-Claude C; Battaglio M; Fiorucci M; Gillet D; Vimort AS; Giraud Y; Laurent S; Vaganay A; Poulet H
Vaccine; 2015 Jul; 33(32):3843-9. PubMed ID: 26144898
[TBL] [Abstract][Full Text] [Related]
22. Development and evaluation of alternative testing methods for the in vivo NIH potency test used for the quality control of inactivated rabies vaccines.
Rooijakkers E; Groen J; Uittenbogarrd J; van Herwijnen J; Osterhaus A
Dev Biol Stand; 1996; 86():137-45. PubMed ID: 8785943
[TBL] [Abstract][Full Text] [Related]
23. Reduction of the number of mice used for potency testing of human and animal rabies vaccines.
Bruckner L; Palatini M; Ackermann M; Müller HK; Kihm U
Experientia; 1988 Oct; 44(10):853-7. PubMed ID: 3181371
[TBL] [Abstract][Full Text] [Related]
24. Inactivated rabies vaccine control and release: use of an ELISA method.
Fournier-Caruana J; Poirier B; Haond G; Jallet C; Fuchs F; Tordo N; Perrin P
Biologicals; 2003 Mar; 31(1):9-16. PubMed ID: 12623055
[TBL] [Abstract][Full Text] [Related]
25. Use of a monoclonal antibody for quantitation of rabies vaccine glycoprotein by enzyme immunoassay.
Lafon M; Perrin P; Versmisse P; Sureau P
J Biol Stand; 1985 Oct; 13(4):295-301. PubMed ID: 3902842
[TBL] [Abstract][Full Text] [Related]
26. Engineering of a recombinant trivalent single-chain variable fragment antibody directed against rabies virus glycoprotein G with improved neutralizing potency.
Turki I; Hammami A; Kharmachi H; Mousli M
Mol Immunol; 2014 Feb; 57(2):66-73. PubMed ID: 24091293
[TBL] [Abstract][Full Text] [Related]
27. Fusion Peptide Improves Stability and Bioactivity of Single Chain Antibody against Rabies Virus.
Xi H; Zhang K; Yin Y; Gu T; Sun Q; Shi L; Zhang R; Jiang C; Kong W; Wu Y
J Microbiol Biotechnol; 2017 Apr; 27(4):718-724. PubMed ID: 28068664
[TBL] [Abstract][Full Text] [Related]
28. Potency test to discriminate between differentially over-inactivated rabies vaccines: Agreement between the NIH assay and a G-protein based ELISA.
Toinon A; Moreno N; Chausse H; Mas E; Nicolai MC; Guinchard F; Jaudinaud I; Guinet-Morlot F; Riou P; Manin C
Biologicals; 2019 Jul; 60():49-54. PubMed ID: 31105021
[TBL] [Abstract][Full Text] [Related]
29. A collaborative study on the use of single radial immunodiffusion for the assay of rabies virus glycoprotein.
Ferguson M; Seagroatt V; Schild GC
J Biol Stand; 1984 Jul; 12(3):283-94. PubMed ID: 6434544
[TBL] [Abstract][Full Text] [Related]
30. In vitro potency tests: challenges encountered during method development.
Yomayuza CL; Thiel HJ; König M
Dev Biol (Basel); 2012; 134():93-100. PubMed ID: 22888600
[TBL] [Abstract][Full Text] [Related]
31. Potency of veterinary rabies vaccines in The Netherlands: a case for continued vigilance.
Rooijakkers EJ; Nieuwenhuijs JH; Vermeulen AA; van Steenis G; Osterhaus AD
Vet Q; 1996 Dec; 18(4):146-50. PubMed ID: 8972063
[TBL] [Abstract][Full Text] [Related]
32. Development and evaluation of a competitive ELISA for estimation of rabies neutralizing antibodies after post-exposure rabies vaccination in humans.
Muhamuda K; Madhusudana SN; Ravi V
Int J Infect Dis; 2007 Sep; 11(5):441-5. PubMed ID: 17321182
[TBL] [Abstract][Full Text] [Related]
33. The rabies peripheral challenge test: more accurate determination of vaccine potency.
Wunderli PS; Dreesen DW; Miller TJ; Baer GM
Vaccine; 2006 Nov; 24(49-50):7115-23. PubMed ID: 16919854
[TBL] [Abstract][Full Text] [Related]
34. Report of a collaborative study to assess the determination of glycoprotein antigen content of rabies vaccines for human use.
Ferguson M; Heath A
Biologicals; 1992 Jun; 20(2):143-54. PubMed ID: 1389110
[No Abstract] [Full Text] [Related]
35. Evaluation of the single radial-immunodiffusion assay for measuring the glycoprotein content of rabies vaccines.
Mayner RE; Needy CF
J Biol Stand; 1987 Jan; 15(1):1-10. PubMed ID: 3104340
[TBL] [Abstract][Full Text] [Related]
36. A time-resolved fluoroimmunoassay for the quantitation of rabies virus nucleoprotein in the rabies vaccine.
Lin G; Huang H; Liu T; He C; Liu J; Chen S; Hou J; Ren Z; Dong W; Wu Y
J Virol Methods; 2014 Sep; 206():89-94. PubMed ID: 24928690
[TBL] [Abstract][Full Text] [Related]
37. Potency, immunogenicity, and efficacy of rabies vaccine: In vitro and in vivo approach.
Akter F; Shamimuzzaman M
Immun Inflamm Dis; 2024 Feb; 12(2):e1198. PubMed ID: 38411335
[TBL] [Abstract][Full Text] [Related]
38. Development and validation of a quantitative competitive ELISA for potency testing of equine anti rabies sera with other potential use.
Korimbocus J; Dehay N; Tordo N; Cano F; Morgeaux S
Vaccine; 2016 Jun; 34(28):3310-6. PubMed ID: 27151880
[TBL] [Abstract][Full Text] [Related]
39. Quantitative determination of rabies antigen by ELISA.
van der Marel P; van Wezel AL
Dev Biol Stand; 1981; 50():267-75. PubMed ID: 7341294
[TBL] [Abstract][Full Text] [Related]
40. A recombinant rabies vaccine expressing the trimeric form of the glycoprotein confers enhanced immunogenicity and protection in outbred mice.
Koraka P; Bosch BJ; Cox M; Chubet R; Amerongen Gv; Lövgren-Bengtsson K; Martina BE; Roose J; Rottier PJ; Osterhaus AD
Vaccine; 2014 Aug; 32(36):4644-50. PubMed ID: 24962755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
